BLASTID, Inc. is developing diagnostic technologies that utilize single-cell analysis to rapidly identify drug-resistant pathogens, addressing the critical issue of antimicrobial resistance. Their platform enhances diagnostic speed and accuracy, enabling timely interventions in global healthcare.
Funding
Funding not disclosed
Founders
Product
Problem
Antimicrobial resistance is a growing global healthcare threat, requiring rapid and accurate identification of drug-resistant pathogens for timely intervention. Current diagnostic methods often lack the speed and precision needed to effectively combat this issue.
Solution
BLASTID is developing diagnostic technologies leveraging single-cell analysis to quickly identify drug-resistant pathogens. Their platform aims to enhance diagnostic speed and accuracy, enabling more effective and timely interventions. By rapidly identifying and assaying individual cells, including drug-resistant pathogens, BLASTID's technology offers a solution to the antimicrobial resistance crisis. The company's approach is designed to set a new standard for speed, accuracy, and patient impact in diagnostic testing.
Target Audience
The primary target audience includes healthcare providers and institutions seeking advanced diagnostic tools for combating antimicrobial resistance.
Features
- Single-cell analysis for rapid pathogen identification
- Enhanced diagnostic speed compared to traditional methods
- Improved accuracy in detecting drug-resistant strains